Drug Profile
Iopofosine I 131 - Cellectar Biosciences
Alternative Names: (131)I-CLR1404; 131-I-NM404; 131I-CLR1404; CLR 1404 I-131; CLR-131; HOT; I-131-CLR1404; NM-404Latest Information Update: 25 Jan 2024
Price :
$50
*
At a glance
- Originator University of Michigan Medical School
- Developer Cellectar Biosciences; University of Wisconsin-Madison
- Class Antineoplastics; Drug conjugates; Iodine radioisotopes; Phospholipid ethers; Radiopharmaceuticals; Small molecules
- Mechanism of Action Ionising radiation emitters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Haematological malignancies; Multiple myeloma; Waldenstrom's macroglobulinaemia
- Phase I/II Non-small cell lung cancer
- Phase I Brain cancer; Glioma; Head and neck cancer; Lymphoma; Solid tumours
Most Recent Events
- 24 Jan 2024 Updated efficacy data from a phase II CLOVER trial in Waldenstrom’s Macroglobulinemia released by Cellectar Biosciences
- 19 Dec 2023 Cellectar Biosciences expands its licensing agreement with the Wisconsin Alumni Research Foundation (WARF) for Iopofosine I 131 for various pediatric solid cancers, such as high-grade glioma, neuroblastoma and sarcoma
- 01 Oct 2023 Phase-I clinical trials in Glioma (In children, In adolescents, In adults) in USA (IV) (NCT05610891)